Legal status
Ibogaine is banned in some countries, a prescription medicine in others, and simply unregulated in many more. The global picture — and why “unregulated” does not mean “safe”.
Three legal categories
Prohibited
Possession and supply are criminal offences.
Medically restricted
Classified as a medicine — lawful only through medical channels.
Unregulated
Not scheduled; clinics operate with no oversight at all.
Ibogaine is not scheduled under the UN drug conventions — every country decides for itself, which is why the map is a patchwork.
Status we can tie to a primary source
Every row below links to the statute, regulation or regulator's own record it rests on. Scheduling is amended regularly, so check the linked text for the version in force before you rely on it.
| Country | Category | Status and instrument |
|---|---|---|
| United States | Prohibited | Schedule I of the Controlled Substances Act, DEA code 7260 — no accepted medical use in the federal scheme and no approved product (21 CFR 1308.11) |
| France | Prohibited | Added to Annex IV of the narcotics list by the order of 12 March 2007, covering Tabernanthe iboga, Tabernanthe manii, ibogaine and their preparations (Légifrance) |
| United Kingdom | Prohibited | No named listing; production, supply and import of psychoactive substances are prohibited by the blanket regime of the Psychoactive Substances Act 2016. Possession alone is not an offence except in custodial settings |
| New Zealand | Medically restricted | Reclassified as a prescription medicine by the Medicines Classification Committee in November 2009 — the clearest framework anywhere (Medsafe minutes) |
| Australia | Medically restricted | Listed in Schedule 4 of the Poisons Standard, which makes it prescription-only rather than prohibited (current Poisons Standard) |
| European Union | Medically restricted | No authorised medicinal product containing ibogaine exists anywhere in the EU; national scheduling then varies state by state (Esperança 2026 review) |
We corrected this page in October 2026. It previously listed Australia as prohibited with no lawful therapeutic products. The Poisons Standard lists ibogaine in Schedule 4, which means prescription-only. The earlier entry was wrong.
The United States, federal and state
US coverage usually stops at "Schedule I", which misses what has changed. Texas has begun funding ibogaine research directly, and it is worth being precise about what that does and does not mean.
| Level | What is in force |
|---|---|
| Federal | Schedule I, DEA code 7260. Treatment outside an authorised research protocol is unlawful, and prosecutions do happen — a Colorado man was sentenced to 48 months for ibogaine distribution in September 2025 (DEA) |
| Texas | Senate Bill 2308 (2025) created a consortium to run FDA drug-development trials of ibogaine and added Chapter 491 to the Health and Safety Code (enrolled bill). The budget appropriated $50 million to HHSC for fiscal 2026 to implement it (SB 1, Art. IX §18.74) |
| Texas, where it stands | HHSC selected UTHealth Houston as lead institution, but as of October 2026 states that plans submitted so far do not meet Chapter 491's requirements on matching funds and intellectual-property revenue (HHSC) |
| Other states | We have found no state that has changed the legal status of ibogaine treatment. Several have considered study or funding bills; none of that makes treatment lawful |
State funding is not legalisation. Texas is paying for trials aimed at eventual FDA approval. Ibogaine remains Schedule I federally, and a state appropriation does not create a lawful route to treatment in Texas or anywhere else in the US.
Countries we could not verify
These appear on almost every ibogaine legal map, and we could not confirm any of them against a statute or regulator record. The secondary sources disagree with each other, many of them are clinic marketing pages, and several are years out of date. We would rather tell you that than repeat a number we cannot stand behind.
| Country | What is claimed, and the problem |
|---|---|
| Thailand | Ibogaine does not appear in the Thai FDA's published traveller lists, but those are explicitly labelled as examples of Schedule II and III narcotics, so its absence there proves nothing. The complete schedules are searchable only through the Thai FDA permit tool and are published in Thai. Secondary sources conflict, and at least one places it in Category 1, the most serious tier. Treat the status as unresolved rather than permissive |
| Brazil | Variously described as prescription-legal in São Paulo from 2016, decriminalised for therapeutic use by ANVISA in 2017, and as a controlled substance. These cannot all be right. Check ANVISA directly |
| South Africa | Described as Schedule 6 prescription-controlled by some sources and as unscheduled by others. Check the Medicines Control Council schedules |
| Gabon | Widely described as legal, with iboga protected as national heritage; export of root bark is also reported to have been restricted since 2019. We could not source either claim to a Gabonese legal text |
| Sweden · Denmark · Norway · Belgium · Switzerland | Commonly listed as prohibited. Plausible, and we found no primary instrument naming ibogaine in any of them |
| Mexico · Costa Rica | Commonly described as unregulated, which is consistent with most treatment happening there. We found no statute to cite either way, because the claim is about an absence |
Where it is unregulated
Most of the world's ibogaine treatment happens where the law is simply silent: Mexico (the de facto hub), Costa Rica, and several Caribbean and Central American jurisdictions. No licence is required, there are no inspections and no outcome register — the openness that makes treatment accessible makes quality entirely your problem to verify. Unregulated is not a safety rating. It means nobody is checking.
Three practical consequences: treatment usually means travel · in unregulated countries the vetting burden is entirely yours · and never transport ibogaine across borders — that is a serious offence everywhere prohibition applies, and the sentence above shows it is enforced.
Sources
Last reviewed October 2026. Legal status changes; the links below are the texts themselves, so you can check the current version rather than trusting this page.
- United States: 21 CFR 1308.11, Schedule I hallucinogenic substances, DEA code 7260 · enforcement example, DEA press release, 25 September 2025
- Texas: S.B. 2308 (89R), enrolled · S.B. 1, General Appropriations Act, Article IX §18.74 · HHSC, Ibogaine Clinical Trials
- France: Arrêté du 12 mars 2007 amending the order of 22 February 1990 listing substances classified as narcotics
- United Kingdom: Psychoactive Substances Act 2016
- New Zealand: Medicines Classification Committee, 42nd meeting minutes, 3 November 2009 · a treatment death and a duty-of-care breach by a legal provider, HDC decision 13HDC00966
- Australia: Therapeutic Goods (Poisons Standard — February 2026) Instrument, Schedule 4
- European Union: Esperança, Gomes & Campos 2026, Molecules 31(3):545 — no authorised medicinal products containing ibogaine in the EU (full text)
Wondering if ibogaine fits your situation?
Six questions, two minutes. A straight answer, and we'll tell you honestly if it's no.